Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
GM

NYSE · GMAB

Genmab A/S

Healthcare · Biotechnology

$57.06

Up+$0.57 (+1.01%)

Updated Oct 31, 2026, 5:33 PM

SID Score

8.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
19.89B
P/E ratio
14.56
Dividend yield
0.00%
52-week range
$23.62 – $59.97
Volume
8.65M
Avg. volume
2.09M

Price performance · GMAB

GMAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

GMAB closed at $57.06 after 21 trading sessions, up 64.20% for the selected period.

Last close
$57.06
Period change
+64.20%
Period low
$34.75
Period high
$57.29
Daily close
View OHLC price history
GMAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$57.40$59.0228$56.53$57.068.65M
Oct 29, 2026$56.56$58.19$55.68$56.496.25M
Oct 28, 2026$44.63$59.97$44.35$57.2929.28M
Oct 27, 2026$44.41$44.99$43.98$44.674.93M
Oct 26, 2026$44.79$45.445$44.08$44.6857.47M
Oct 23, 2026$39.84$44.34$39.635$43.7913M
Oct 22, 2026$39.675$40.165$39.50$40.004.69M
Oct 21, 2026$39.08$39.66$39.05$39.572.97M
Oct 20, 2026$38.60$39.405$38.415$39.073.78M
Oct 19, 2026$37.89$39.00$37.76$38.504.78M
Oct 16, 2026$38.145$38.20$36.74$37.002.68M
Oct 15, 2026$37.20$38.33$37.04$37.824.08M
Oct 14, 2026$36.385$37.245$36.125$36.892.69M
Oct 13, 2026$37.23$37.35$36.34$36.573.74M
Oct 12, 2026$37.18$37.71$36.94$37.373.13M
Oct 9, 2026$36.55$37.15$36.33$37.072.33M
Oct 8, 2026$36.175$36.285$35.09$36.054.3M
Oct 7, 2026$37.28$37.87$36.27$36.654.25M
Oct 6, 2026$39.11$39.15$37.07$37.806.6M
Oct 5, 2026$35.09$40.17$35.02$38.4812.4M
Oct 2, 2026$34.39$35.02$33.725$34.755.44M

Latest GMAB news

The latest Smart Investors Daily articles mentioning GMAB.

Stock researchCompany · Overview

GMAB research

Overview

Company profile and research snapshot.

Company profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.25
Implied upside
—
Analysts
—
GMAB recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 23, 2026JYSKE BANKBuy—
Sep 14, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Aug 31, 2026BNP PARIBASOutperform—
Aug 7, 2026DNB CARNEGIEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?

Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte co funding and supplying its KRAS G12D inhibitor. The partnership gives Incyte deeper exposure to gastrointestinal oncology through a KRAS targeted combination approach, timed alongside fresh oncology data at the ESMO 2026 Congress that can shape...

Yahoo · Oct 24, 2026

Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration

Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer. The study will test a combination of Genmab’s bispecific antibody with Incyte’s selective KRAS G12D inhibitor in first-line treatment settings. The collaboration adds a fresh colorectal cancer program to Incyte’s pipeline that focuses on a mutation frequently found in these patients. The new KRAS G12D metastatic colorectal cancer trial is important, but it...

Yahoo · Oct 24, 2026

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By